Related Experiment Video
Updated: Jul 13, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
[Helicobacter pylori detected in atheroma plaque]
G Ghirardi1, F Maldonado, L Guzmán
1Servicio de Anatomía Patológica y Departamento de Cardiologia, Hospital Córdoba, Córdoba, Argentina.
Introduction:
In general, infection and chronic inflammation have been implied as etiologic agents for atheroesclerosis and in particular coronary illness (CI). Several studies have correlated the infection of Helicobacter pylori with CI, especially with virulent strains (lineage Cag A).
Objective:
Demonstrate the immunohistochemical presence of H. Pylori in atheroscletotic plaques obtained from endarterectomy of different vascular regions.
Material And Methods:
34 atherosclerotic plaques of different vascular areas were studied, (25 men and 9 women). The tissues were fixed with 10% neutral buffered-formalin and decalcifying in formic acid 5% was used when necessary. The tissue sections were included in paraffin, cut and colored with H&E and subjected to Immunohistochemistry (IHC) of H. Pylori. Briefly, tissues were deparaffinized and thermally treated with a citrate-based solution of antigenic retrieval (ImmunoDNA Retriever with Citrate, BIO SB, Santa Barbara, CA) using a water bath at 95 degrees C for 1 hour. The IHC was conducted using a high sensitivity Biotin-Streptavidin-HRP-DAB IHC system (ImmunoDetector HRP/DAB, BIO SB). The microscopic observation evaluated the presence of mononuclear inflammatory cells and the identification of the bacteria in the wall or the vascular lumen.
Results:
Of the 34 cases studied 14 were positive, where one could identify the bacillus in their different forms (41,17%) associated with chronic inflammation.
Related Concept Videos
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Gastritis II: Pathophysiology
Peptic Ulcer
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
